SOAP Note for 37-Year-Old Male with Acid Reflux and Associated Symptoms
For this patient presenting with intermittent acid reflux, indigestion, and chest pain, I recommend starting a proton pump inhibitor (PPI) rather than famotidine, as PPIs are the first-line therapy for GERD symptoms and provide superior acid suppression. 1
SUBJECTIVE
Chief Complaint:
Intermittent acid reflux, indigestion, occasional chest pain, and tingling in face and hands.
History of Present Illness:
37-year-old male reports intermittent episodes of acid reflux and indigestion. Experiences occasional chest pain (character, duration, and radiation not specified but warrants cardiac evaluation given atypical features). Also notes tingling sensations in face and hands occurring intermittently. Works outdoors. Denies heavy caffeine use. No prior episodes or previous treatment for reflux symptoms.
Past Medical History:
- Cholecystectomy ([DATE])
- No other significant medical history
Medications:
None
Allergies:
None documented
Social History:
Works outdoors. Denies heavy caffeine consumption.
Review of Systems:
- Cardiovascular: Occasional chest pain (requires further characterization)
- Gastrointestinal: Acid reflux, indigestion
- Neurological: Tingling in face and hands
OBJECTIVE
Vital Signs:
[To be documented at visit]
Physical Examination:
[To be performed and documented, with particular attention to:]
- Cardiovascular: Heart sounds, rhythm, murmurs
- Abdominal: Epigastric tenderness, surgical scars from cholecystectomy, organomegaly
- Neurological: Sensory examination of face and hands, assessment for paresthesias
Diagnostic Studies:
Pending (see Plan)
ASSESSMENT
Gastroesophageal Reflux Disease (GERD), unspecified – ICD-10: K21.9
- Presenting with typical reflux symptoms (heartburn, indigestion) without alarm features
- No prior endoscopy or objective testing
Chest pain, unspecified – ICD-10: R07.9
- Requires evaluation to exclude cardiac etiology given atypical presentation with facial/hand tingling
- May represent non-cardiac chest pain related to GERD, but cardiac workup indicated first
Paresthesia of skin – ICD-10: R20.2
- Tingling in face and hands; differential includes anxiety/hyperventilation, electrolyte abnormalities, vitamin deficiencies, or neurological conditions
- Outdoor work raises consideration of heat-related issues or occupational exposures
PLAN
Medication Adjustment from Requested Regimen:
Your proposed famotidine 40 mg twice daily PRN is not the optimal choice. Current AGA guidelines recommend a 4- to 8-week trial of once-daily PPI therapy as first-line treatment for patients presenting with typical reflux symptoms without alarm features 1. PPIs provide superior acid suppression compared to H2-receptor antagonists like famotidine 2.
If you prefer to use famotidine despite guideline recommendations, the FDA-approved dosing for symptomatic non-erosive GERD is 20 mg twice daily (not 40 mg twice daily), and it should be taken regularly (not PRN) for up to 6 weeks 3. The 40 mg twice daily dosing is reserved for erosive esophagitis confirmed by endoscopy 3.
Recommended Treatment Plan:
Pharmacotherapy:
- Prescribe: Omeprazole 20 mg PO once daily before breakfast for 4-8 weeks (or equivalent PPI)
- Counsel patient on PPI safety 1
- If inadequate response after 4 weeks, may increase to twice-daily dosing
- Once symptoms controlled, titrate to lowest effective dose
Lifestyle Modifications:
- Provide education on GERD mechanisms 1
- Weight management if applicable
- Avoid late-night meals (stop eating 3 hours before bedtime)
- Elevate head of bed 6-8 inches
- Avoid trigger foods (fatty foods, chocolate, alcohol, mint, spicy foods)
- Smoking cessation if applicable
Cardiac Evaluation (URGENT):
- ECG today – CPT: 93000 (to rule out cardiac etiology of chest pain)
- Consider troponin if chest pain is acute or concerning features present
- The combination of chest pain with facial/hand tingling raises concern for cardiac vs. anxiety-related etiology
Laboratory Studies:
- Comprehensive Metabolic Panel (CMP) – CPT: 80053 (evaluate electrolytes given paresthesias; assess renal function before long-term PPI use)
- Complete Blood Count (CBC) – CPT: 85025 (screen for anemia which could indicate GI bleeding)
- Magnesium level – CPT: 83735 (paresthesias may indicate hypomagnesemia; also relevant for PPI monitoring)
- Vitamin B12 level – CPT: 82607 (paresthesias differential; also baseline before long-term PPI)
- Calcium level (included in CMP) – relevant for paresthesias
Follow-Up and Monitoring:
- Return in 4-6 weeks to assess symptom response
- If symptoms persist despite PPI trial: Consider upper endoscopy (CPT: 43235) and/or ambulatory pH monitoring off medication 1
- Red flags requiring urgent endoscopy: dysphagia, odynophagia, weight loss, GI bleeding, persistent vomiting 1
- If PPI continued beyond 12 months, offer objective testing (endoscopy ± pH monitoring) to confirm GERD diagnosis 1
Paresthesia Workup:
- If labs normal and cardiac causes excluded, consider neurology referral if symptoms persist
- Assess for anxiety/panic disorder given constellation of chest pain and paresthesias
Important Caveats:
- Cholecystectomy history: Research shows cholecystectomy does not increase gastroesophageal or duodenogastric reflux 4, so his prior surgery is unlikely related to current symptoms
- Outdoor work: Consider heat exposure, dehydration, or occupational factors contributing to symptoms
- Chest pain requires cardiac clearance first before attributing solely to GERD, especially with atypical features (facial/hand tingling)
- Do not use famotidine PRN – acid suppression requires consistent dosing for efficacy 3
CPT CODES SUMMARY:
- 99203 or 99204 (New patient office visit, depending on complexity)
- 93000 (ECG)
- 80053 (Comprehensive Metabolic Panel)
- 85025 (Complete Blood Count with differential)
- 83735 (Magnesium)
- 82607 (Vitamin B12)
ICD-10 CODES SUMMARY:
- K21.9 (Gastroesophageal reflux disease without esophagitis)
- R07.9 (Chest pain, unspecified)
- R20.2 (Paresthesia of skin)
Patient education provided regarding GERD pathophysiology, lifestyle modifications, PPI safety, and importance of cardiac evaluation. Shared decision-making discussion documented. Patient agrees with plan.